Trial Profile
Phase 3, Randomized, Open-label, Controlled, Multiple-Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to lesser than 18 Years of age With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Renal failure; Secondary hyperparathyroidism
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 08 Dec 2022 Planned End Date changed from 29 Jun 2026 to 30 Jan 2026.
- 13 Jul 2022 Planned End Date changed from 31 Jan 2023 to 29 Jun 2026.
- 13 Jul 2022 Planned primary completion date changed from 31 Jan 2023 to 30 Jan 2026.